Founded in 1993, the Cancer Therapeutics Program is a multidisciplinary and interdepartmental research effort that utilizes both early and late stage clinical trials as the fundamental experimental approach to develop novel therapies for cancer. Investigators in the Cancer Therapeutics Program participate in all levels of drug development, ranging from providing scientific rationale in preclinincal studies, to establishing proof of concept in phase I and II studies, and ultimately to redefining standard of care using novel approaches in large randomized phase III studies. Primary emphasis in this Program is placed on novel agents that are mechanistically defined with multiple potential clinical indications (e.g. kinase inhibition, anti-angiogenesis, immune therapy) rather than therapeutic strategies that are primarily organ restricted or empiric. The primary goal of the Cancer Therapeutics Program is to stimulate synergistic interactions among basic, translational, and clinical investigators who are dedicated to new drug development based on the emerging science of cancer biology. In particular, the Program aims to provide a scientific avenue for laboratory-based investigators to interact with clinical investigators to facilitate the bench-to-bedside translation of scientific discoveries to clinical research.